PROCEPT BioRobotics Reports Solid Q1 Revenue Growth, Reaffirms FY2026 Guidance, and Announces FDA Clearance

summarizeSummary

PROCEPT BioRobotics reported solid Q1 2026 revenue growth of 20% and improved gross margins, while reaffirming its full-year 2026 financial guidance despite recent operational realignment. The company also announced FDA clearance for its second-generation FirstAssist AI™ software.

check_boxKey Events

• Q1 2026 Financial Results

  Reported total revenue of $83.1 million, a 20% increase year-over-year, driven by strong U.S. system sales and improved pricing. Gross margin improved to 65% from 64% in the prior year period. Net loss increased to $31.6 million from $24.7 million, reflecting continued investment in growth initiatives.

• Full Year 2026 Guidance Reaffirmed

  The company reiterated its full-year 2026 revenue guidance of $390 million to $410 million (27% to 33% growth) and adjusted EBITDA loss guidance of $30 million to $17 million, signaling confidence despite recent commercial realignment.

• FDA Clearance for Enhanced AI Software

  Received FDA clearance for its second-generation FirstAssist AI™ software, which enhances personalized, image-guided planning for Aquablation therapy and strengthens the capabilities of the HYDROS robotic system.

• Operational Realignment Underway

  CEO Larry Wood noted decisive actions to reset the organization, focusing on operational excellence and commercial discipline. While acknowledging some near-term disruption, the company expects benefits to build through the year.

auto_awesomeAnalysis

This 8-K provides a comprehensive update on PROCEPT BioRobotics' Q1 2026 performance and strategic direction. While the company delivered solid 20% revenue growth and improved gross margins, the net loss increased due to continued investment in commercial expansion and R&D. A key takeaway is the reaffirmation of full-year 2026 guidance, which signals management's confidence in achieving its targets despite acknowledging "near-term disruption" from a commercial realignment. The FDA clearance for its enhanced AI software is a positive product development, strengthening the HYDROS robotic system's capabilities and supporting future growth. Investors will likely focus on the company's ability to execute its operational reset and translate product innovation into sustained profitability.